Shares of FIGS Inc. maintained their elevated position in after-hours trading, hovering near $15.40 following a dramatic 23.9% surge during Friday's regular session that pushed the stock to a close of $15.45. The sharp move came after the medical apparel company released fourth-quarter financial results that exceeded expectations, though management simultaneously highlighted significant challenges ahead related to tariffs and profitability.
Strong Quarterly Performance Amid Challenges
The company reported net revenue for the fourth quarter soared 33% year-over-year to $201.9 million, demonstrating robust demand for its healthcare apparel. Net income reached $18.5 million, or $0.10 per diluted share, marking a positive swing for the business. However, the results contained concerning signals about the company's margin structure, with gross margin declining 440 basis points to 62.9%. Management attributed this contraction to increased tariff costs and a $5.6 million inventory write-off.
Chief Executive Officer Trina Spear characterized 2025 as a "remarkable" year for the business, pointing to solid performance across operations. The executive emphasized the company's positioning in what she described as a "replenishment-driven" and "non-cyclical" uniform market, suggesting a degree of insulation from broader economic fluctuations that affect consumer discretionary stocks.
Forward Guidance and Financial Position
Looking ahead, FIGS provided its initial outlook for fiscal year 2026, projecting net revenue growth in the range of 10% to 12%. This guidance incorporates an assumed 15% "global tariff" rate, indicating that international trade policies are now a central component of the company's financial planning. Chief Financial Officer Sarah Oughtred noted the tariff landscape remains "fluid," introducing uncertainty into future cost structures.
The company ended 2025 with a strong liquidity position, holding $300.8 million in net cash, cash equivalents, and short-term investments. Additionally, the board has authorized $52 million for share repurchases, providing potential support for the stock price. This financial flexibility may prove valuable as FIGS navigates the challenging operating environment ahead.
Market Context and Investor Sentiment
The substantial single-day gain represents a dramatic reversal for a stock that has faced pressure to demonstrate a sustainable return to growth following what executives previously termed a post-pandemic "overhang" in demand for scrubs and related medical gear. Investors are now attempting to parse how much of the rebound stems from fundamental improvements in products, inventory management, and pricing versus a broader recovery in the consumer sector after a difficult period.
Monday's trading session will serve as a critical test of whether the stock can maintain its newly established premium valuation. Market participants will be watching closely to see if steady demand materializes as the company adjusts its pricing and promotional strategies in response to cost pressures. The recent rally has attracted short-term speculative capital, potentially increasing volatility in the coming sessions.
Tariff Pressures and Margin Risks
A significant concern for investors centers on the company's exposure to escalating tariffs, which management has explicitly flagged as already affecting financial results. Should these import costs exceed current projections, or if healthcare professionals prove resistant to price increases passed along by the company, FIGS' margins could deteriorate rapidly. This risk appears particularly acute following the stock's sharp appreciation, which has raised performance expectations for subsequent quarters.
The margin compression witnessed in the fourth quarter, driven by both tariffs and inventory adjustments, suggests the company's path to maintaining profitability while growing revenue may prove challenging. Investors will be scrutinizing management's ability to balance these competing priorities through operational efficiencies and strategic pricing.
Upcoming Catalysts and Communication
Market attention now turns to management's scheduled appearance at the Raymond James 47th Annual Institutional Investors Conference on March 4. Investors anticipate additional details regarding demand trends, pricing strategies, and the company's approach to navigating the evolving tariff environment during this fireside chat. This communication represents the next opportunity for leadership to either reinforce or temper the optimism reflected in Friday's price action.
Following this event, focus will shift toward the next earnings report, which market calendars tentatively suggest may occur around May 7, though the company has not yet formally confirmed this date through its official channels. The interim period will allow investors to assess whether the positive momentum from the fourth quarter can be sustained into the new fiscal year amidst the acknowledged headwinds.
